New York, Feb 24, 2026, 05:51 ET — Premarket
- IBRX climbed roughly 1% in premarket trading, adding to strong gains posted in the previous session.
- Company posted ANKTIVA net product revenue for 2025 at roughly $113 million.
- Investors are watching for follow-through at the open, and also keeping an eye on the next regulatory moves slated for 2026.
ImmunityBio was up roughly 1% in premarket action Tuesday, following a surge in buying after the company issued fresh details on ANKTIVA sales and announced new market clearances. Shares finished Monday at $9.83, jumping about 13% on much heavier-than-normal trading volume.
This is notable: ImmunityBio, for a change, joins the smaller biotech crowd with an actual product on the market and a revenue stream that’s finally taking shape—giving investors figures to work with instead of just debates.
Traders have shown little hesitation snapping up anything suggesting demand could return, particularly if it brings fresh markets or new oncology opportunities. The flipside? They’ve just as swiftly hit sell when those signals aren’t there.
ImmunityBio reported ANKTIVA net product revenue surged around 700% year over year in 2025, hitting approximately $113 million, with $38.3 million booked in the fourth quarter alone. For 2025, net loss attributable to common stockholders came to $351.4 million. The company ended the year with $242.8 million in cash, cash equivalents and marketable securities. Founder and executive chairman Patrick Soon-Shiong described the Saudi lung-cancer authorization as “a defining moment.” CEO Richard Adcock said ImmunityBio is focused on “disciplined execution,” with a biologics license application, or BLA, for a bladder-cancer trial planned in the fourth quarter of 2026. Business Wire
The company posted its business update and financial results on Monday, filing the release as an 8-K, according to a regulatory disclosure.
ImmunityBio is marketing ANKTIVA (nogapendekin alfa inbakicept) as an immune-boosting therapy for early-stage bladder cancer. The treatment pairs with BCG, a decades-old bladder cancer drug that relies on a weakened bacterium to stimulate the immune system.
The company announced that its bladder-cancer indication has secured authorization in the United States, the United Kingdom, the European Union, and Saudi Arabia—bringing the total to 33 countries. It also noted a response had been sent to the U.S. FDA with extra data specific to papillary-only bladder cancer and is now waiting for feedback from the agency.
ImmunityBio disclosed that Saudi regulators gave ANKTIVA a conditional accelerated nod back in January, for use with checkpoint inhibitors in metastatic non-small cell lung cancer. The company is targeting a commercial rollout in Saudi Arabia within 60 days after that approval. Checkpoint inhibitors—drugs that release immune cells from inhibition—remain central to lung-cancer treatment.
Monday’s pop aside, the setup remains messy. Conditional or accelerated approvals usually bring strings attached—follow-up demands, plus expansion plans that can stumble on timing, supply issues or reimbursement hurdles.
Tuesday’s key question: Does Monday’s volume spike lead to real follow-through buying once the market opens, or does it slip right back into profit-taking? Moves in biotech momentum names rarely last long.
